P/E at 36.75 vs Industry's 36.99: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: A Close Match to Industry Norms

The current P/E of Sun Pharmaceutical Industries Ltd stands at 36.75, marginally below the Pharmaceuticals & Biotechnology industry average of 36.99. This near equivalence suggests that the market is pricing the stock in line with its sector peers, reflecting neither a significant premium nor a discount. Such valuation alignment often indicates that investors are factoring in the company’s fundamentals and growth prospects similarly to the broader industry. However, the subtle difference could also imply slight caution or optimism depending on other performance metrics and market sentiment. Previously rated Hold, what is Sun Pharmaceutical Industries Ltd’s current rating? The four-parameter analysis factors in the valuation premium.

Performance Across Timeframes: Strong Long-Term Gains with Mixed Short-Term Signals

Examining the stock’s returns reveals a compelling long-term performance story. Over one year, Sun Pharmaceutical Industries Ltd has delivered an 18.02% gain, significantly outperforming the Sensex’s decline of 3.34% during the same period. This outperformance extends further back, with three-year returns at 70.90% versus the Sensex’s 19.17%, and five-year returns surging 148.76% compared to the Sensex’s 40.42%. Even the 10-year return of 141.33% remains robust, though it trails the Sensex’s 176.52% over that timeframe.

Yet, the short-term momentum is less clear-cut. The stock’s one-month gain of 0.57% slightly exceeds the Sensex’s 0.30%, and the three-month return of 6.06% also outperforms the Sensex’s 4.34%. However, the one-week performance shows a modest decline of 0.46%, though still better than the Sensex’s 1.40% drop. The one-day performance is flat at 0.00%, marginally outperforming the Sensex’s 0.15% fall. This divergence between short-term softness and longer-term strength raises the question: is this a temporary pause or a sign of shifting momentum?

Moving Average Configuration: Signs of Recovery Amidst Caution

The technical picture for Sun Pharmaceutical Industries Ltd is nuanced. The stock currently trades above its 5-day, 50-day, 100-day, and 200-day moving averages, indicating underlying strength and a potential recovery from recent lows. However, it remains below the 20-day moving average, suggesting some short-term resistance or consolidation. This configuration often signals a stock that is rebounding within a broader trend but has yet to confirm a sustained upward momentum. The recent gain after two consecutive days of decline supports this interpretation, but the question remains: is this a genuine recovery or a relief rally that will fade at the 50 DMA?

Sector Context: Mixed Results Amidst Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen a mixed bag of results recently. Out of 22 stocks that have declared results, 11 reported positive outcomes, 8 remained flat, and 3 posted negative results. This distribution suggests a sector experiencing moderate growth with pockets of stability and some areas of concern. Within this environment, Sun Pharmaceutical Industries Ltd appears to be holding its ground, outperforming many peers in terms of returns and maintaining a valuation close to the industry average. This sector backdrop adds context to the stock’s performance and valuation, raising the question: how will sector trends influence the stock’s near-term prospects?

Rating Context: Previously Rated Hold, Now Reassessed

MarketsMOJO had previously assigned a Hold rating to Sun Pharmaceutical Industries Ltd. This rating was updated on 8 June 2026, reflecting a reassessment of the company’s fundamentals, valuation, and technical indicators. While the current rating is not disclosed, the change signals a shift in the analytical view based on recent data. The stock’s strong long-term returns, near-parity valuation with the sector, and mixed short-term technical signals all contribute to this reassessment. Should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Conclusion: A Balanced Valuation with Divergent Momentum Signals

The data on Sun Pharmaceutical Industries Ltd presents a stock trading at a valuation closely aligned with its sector, supported by strong long-term performance and a mixed but cautiously optimistic technical setup. The stock’s outperformance over one, three, and five years contrasts with some short-term volatility and resistance near the 20-day moving average. Sector results are broadly mixed, adding complexity to the outlook. The recent rating reassessment from Hold reflects these nuanced factors, underscoring the importance of weighing both valuation and momentum in any analysis.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →